Moderna Names Michael Mullette as Managing Director of New Canadian Subsidiary
September 10 2020 - 08:00AM
Business Wire
Moderna expands footprint in North America with
Canadian subsidiary; permanent presence to support delivery of mRNA
vaccines and therapeutics to Canadians
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines to create a new
generation of transformative medicines for patients, today
announced the appointment of Michael Mullette as Managing Director,
Canada effective immediately.
Mr. Mullette will establish a permanent presence for Moderna in
Canada as an expansion to Moderna’s North America footprint at a
time when the company is scaling up operations for late-stage
development and large scale manufacturing of mRNA-1273, its
investigational vaccine against COVID-19. A Phase 3 study of
mRNA-1273 in the U.S. has already enrolled over two-thirds of
participants and follows the publication of interim results from
the Phase 1 study, led by the U.S. National Institutes of Health
and published in The New England Journal of Medicine, demonstrating
that mRNA-1273 induced rapid and strong immune responses against
SARS-CoV-2.
“I am honored to take on the task of making Canada home to
Moderna’s expanded North American footprint and to start building a
strong local team,” said Mr. Mullette. “Having spent time working
in the Canadian public health system, I know just how much interest
there is across the country in Moderna’s progress in bringing a
COVID-19 vaccine to market. My focus will be to deliver on those
expectations and support access to Moderna’s innovative mRNA
platform for Canadian citizens.”
Mr. Mullette joined Moderna in August 2020 as Vice President,
Market Access, and will continue to operate in that role. He brings
a deep familiarity with the Canadian health care system and
biopharmaceutical industry to the company, having spent the
previous two years in Montreal as General Manager and Country Chair
for Sanofi Canada, and a further 19 years in progressively senior
roles with Sanofi Pasteur.
Moderna remains on track to be able to deliver up to 56 million
doses of doses of its COVID-19 vaccine to help protect Canadians
beginning in 2021. The Canadian vaccine supply will be sourced from
Moderna’s European production capacity with its strategic
manufacturing partner Lonza of Switzerland, and ROVI of Spain for
fill-finish manufacturing outside of the U.S.
“With Moderna’s vaccine candidate for COVID-19 now in Phase 3
clinical trials, we are delighted to have Michael with us to help
deliver mRNA solutions to Canadians,” said Stéphane Bancel, CEO of
Moderna. “Michael brings a wealth of first-hand experience not only
in the sector, but in working with Canada’s unique public health
and health care systems.”
Moderna’s decision to establish a local subsidiary reflects
Moderna’s positive experience with Canada’s partnership-driven
approach to public health and the productive working relationship
it has built with federal and provincial health officials.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and the Biomedical Advanced Research and Development
Authority (BARDA), a division of the Office of the Assistant
Secretary for Preparedness and Response (ASPR) within the U.S.
Department of Health and Human Services (HHS). Moderna has been
named a top biopharmaceutical employer by Science for the past five
years. To learn more, visit www.modernatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding the Company’s development of
a potential vaccine against the novel coronavirus, the potential
for mRNA-1273 to prevent COVID-19 disease and slow the spread of
SARS-CoV-2, plans for expansion into the Canadian market, the
supply of mRNA-1273 to the Canadian government, and plans for the
manufacturing and distribution of mRNA-1273. In some cases,
forward-looking statements can be identified by terminology such as
“will,” “may,” “should,” “could”, “expects,” “intends,” “plans,”
“aims,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” “continue,” or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. The forward-looking statements in this press
release are neither promises nor guarantees, and you should not
place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties, and other
factors, many of which are beyond Moderna’s control and which could
cause actual results to differ materially from those expressed or
implied by these forward-looking statements. These risks,
uncertainties, and other factors include, among others: the fact
that there has never been a commercial product utilizing mRNA
technology approved for use; the fact that the rapid response
technology in use by Moderna is still being developed and
implemented; the fact that the safety and efficacy of mRNA-1273 has
not yet been established; potential adverse impacts due to the
global COVID-19 pandemic such as delays in regulatory review,
manufacturing and clinical trials, supply chain interruptions,
adverse effects on healthcare systems and disruption of the global
economy; and those other risks and uncertainties described under
the heading “Risk Factors” in Moderna’s most recent Quarterly
Report on Form 10-Q filed with the U.S. Securities and Exchange
Commission (SEC) and in subsequent filings made by Moderna with the
SEC, which are available on the SEC’s website at www.sec.gov.
Except as required by law, Moderna disclaims any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new
information, future developments or otherwise. These
forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200910005260/en/
Canadian Media Inquiries
Paul Monlezun +1 613-222-7184
paul.monlezun@publicaffairsadvisors.com
Moderna Contacts
Media: Colleen Hussey Senior Manager, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024